Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852595 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL29217207 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL4806245 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL397520 | 1.00 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3HTR3A | |
| SCHEMBL2380059 | 0.87 | CHRNB2 (0.32) | HTR3A | |
| SCHEMBL24510486 | 0.83 | — | — | |
| SCHEMBL13986819 | 0.83 | — | — | |
| SCHEMBL24510485 | 0.83 | — | — | |
| SCHEMBL20758368 | 0.83 | CCR5 (0.33) | HTR3A | |
| SCHEMBL24509726 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112513036-B | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | 福马治疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3793997-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | Forma Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | SLC6A2 4138/4885SLC6A4 4106/4885SLC6A3 3497/4885 |
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, H1-3, HRH4 | SLC6A2 485/4885SLC6A4 847/4885SLC6A3 217/4885 |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | SLC6A2 2308/4885SLC6A4 2503/4885SLC6A3 1918/4885 |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | SLC6A2 4138/4885SLC6A4 4106/4885SLC6A3 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.